Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 13 Most Profitable Growth Stocks to Buy Right Now. Alec Stranahan of Bank of America reaffirmed a Sell rating on TG Therapeutics, Inc. (NASDAQ:TGTX) with a price target of $15, based on the report released on February 27. The firm’s price target is the lowest among Wall Street analysts, based on 8 analysts covering the stock, and it reflects a 49% downside from the current levels.

The rating came after TG Therapeutics, Inc. (NASDAQ:TGTX) reported its fourth-quarter financial results on  February 26. Net income for the quarter reached $23 million, bringing full-year net income to $447.2 million. The company generated total global revenue of $616 million for 2025, including $594 million from U.S. BRIUMVI net product sales and $12.8 million from Neuraxpharm.

Operating expenses for the year reached about $328 million. For 2026, operating expenses are projected at $350 million, plus an additional $100 million for subcutaneous manufacturing and start-up activities.

TG Therapeutics, Inc. (NASDAQ:TGTX) Chief Commercial Officer, Adam Waldman, commented on the outlook:

Turning to the first quarter … We expect U.S. revenue to grow sequentially over Q4 levels to approximately $185 million to $190 million.

TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company. The company focuses on the development, commercialization, and acquisition of novel treatments for B-cell-mediated diseases across the United States and globally. It is based in Morrisville, North Carolina.

While we acknowledge the risk and potential of TGTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TGTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and Goldman Sachs Value Stocks: 10 Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.